Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arthritis Prevention In the Pre-clinical Phase of Rheumatoid Arthritis with Abatacept: a randomised controlled trial

Next Previous
Trial Profile

Arthritis Prevention In the Pre-clinical Phase of Rheumatoid Arthritis with Abatacept: a randomised controlled trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary)
  • Indications Arthralgia; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms APIPPRA

    • Most Recent Events

    • 20 Feb 2024 Results assessing the feasibility, efficacy, and acceptability of treating high risk individuals with the T-cell co-stimulation modulator abatacept published in the Internet Document.
    • 20 Feb 2024 Primary endpoint has been met. (The time to development of clinical synovitis in three or more joints or rheumatoid arthritis according to the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria, whichever was met first, and where joint involvement was defined as joint swelling determined by two independent assessors. In either case, synovitis in nominated joints was confirmed by...)
    • 15 Nov 2023 Results assessing feasibility, efficacy and acceptability of T-cell co-stimulation modulation with abatacept in individuals at risk of developing RA in the Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept (APIPPRA) study presented at the ACR Convergence 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top